ArticleDisease markers2015
Immunoexpression of Ki-67, MCM2, and MCM3 in Ameloblastoma and Ameloblastic Carcinoma and Their Correlations with Clinical and Histopathological Patterns.
Article in Disease markers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- FAM20A Deficiency Drives Transcriptomic Dysregulation and Functional Impairment in Gingival Fibroblasts.Cell proliferation · 2026Article
- Mandibular Hemangiomatous Ameloblastoma: A Case Report and Literature Review.Case reports in dentistry · 2026Article
- The Differences in Expression of Tumor Marker KI-67 and Proliferation Cell Nuclear Antigen (PCNA) in Ameloblastoma with Histopathological Subtypes Follicular, Plexiform, and Mixed (Follicular-Plexiform).European journal of dentistry · 2025Article
- Investigation of survivin and autophagy marker expression in different Indian cancer tissue samples.Journal of molecular histology · 2025Article
- PCNA and MCM 2 in Odontogenic Tumors: An Immunnohistological Study.Journal of pharmacy & bioallied sciences · 2025Article
- Ameloblastic Carcinoma: A 40-Year Scoping Review of the Literature.Current issues in molecular biology · 2025Review
- Immunohistochemical Expression of MDM2, Bcl-2, SATB2 and Ki-67 in Histological Variants of Unicystic Ameloblastoma.Head and neck pathology · 2024Article
- Title of the article: diagnostic markers for odontogenic tumors: an insight: a review.Discover oncology · 2024Review
- Immunohistochemical Expression of Ki-67 and p53 and Their Prognostic Role in Ameloblastoma: A Longitudinal Study.Oman medical journal · 2024Article
- Prognostic value of the expression and localization of cell proliferation and apoptosis markers in unicystic ameloblastomas.Scientific reports · 2024Article
- Function and Therapeutic Potential of Non-Coding RNA in Ameloblastoma.OncoTargets and therapy · 2024Review
- Association of High Immunohistochemical Expression of Minichromosome Maintenance 3 with Human Oral Squamous Cell Carcinoma-A Preliminary Study.Diagnostics (Basel, Switzerland) · 2022Article
- Diagnostic and prognostic value of MCM3 and its interacting proteins in hepatocellular carcinoma.Oncology letters · 2020Article
- A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.Oncology research · 2020Article
- Elevated expression of minichromosome maintenance 3 indicates poor outcomes and promotes G1/S cell cycle progression, proliferation, migration and invasion in colorectal cancer.Bioscience reports · 2020Article
- Evaluation of B Cell ProliferationBio-protocol · 2020Article
- Benign odontogenic ghost cell lesions revisited and new considerations on dysplastic dentin.Clinical oral investigations · 2019Article
- Upregulation of microRNA‑194‑5p inhibits hypopharyngeal carcinoma cell proliferation, migration and invasion by targeting SMURF1 via the mTOR signaling pathway.International journal of oncology · 2019Article
- Expression of parathyroid hormone related protein (PTHRP) in ameloblastomas.Journal of clinical and experimental dentistry · 2018Article
- Minichromosome maintenance protein 2 and 3 promote osteosarcoma progression via DHX9 and predict poor patient prognosis.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell proliferation assays are performed using antibodies against nuclear proteins associated with DNA replication. These nuclear proteins have gained special interest to predict the biological and clinical behaviors of various tumors. The aim of this study was to analyze the presence of Ki-67 protein and the minichromosome maintenance-2 (MCM2) and maintenance-3 (MCM3) proteins in ameloblastoma. Materials and Methods. Cell proliferation marker expression levels were assessed via immunohistochemistry in 111 ameloblastoma cases (72 unicystic ameloblastoma samples, 38 solid/multicystic ameloblastoma samples, and 1 ameloblastic carcinoma). The label index was performed as described previously. Results. MCM2 and MCM3 showed higher proliferation indexes in all variants of ameloblastoma compared to the classic marker Ki-67. No correlation between the proliferation index and the clinical and protein expression data was observed. Conclusion. The results suggest that clinical features do not directly affect tumor cell proliferation. Moreover, the high levels of cellular proliferation of MCM2 and MCM3 compared with Ki-67 may indicate that MCM2 and MCM3 are more sensitive markers for predicting the growth rate and eventually might be helpful as a tool for predicting aggressive and recurrent behaviors in these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.